NEW YORK (AP) — NEW YORK (AP) — Intra-Cellular Therapies Inc. (ITCI) on Tuesday reported a loss of $15.2 million in its first quarter.

On a per-share basis, the New York-based company said it had a loss of 16 cents.

The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 31 cents per share.

The biopharmaceutical company posted revenue of $144.9 million in the period, which also topped Street forecasts. Five analysts surveyed by Zacks expected $141.9 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ITCI at https://www.zacks.com/ap/ITCI

For copyright information, check with the distributor of this item, STATS Perform dba Automated Insights. , source Associated Press News